BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24124705)

  • 21. [What is the REAL long-term risk of proton pump inhibitors?].
    Ribiere S; Guillaumot MA; Barré A; Abou Ali E; Barret M; Chaussade S; Coriat R
    Presse Med; 2019 May; 48(5):503-510. PubMed ID: 30926204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indications and safety of proton pump inhibitor drug use in patients with cancer.
    Triadafilopoulos G; Roorda AK; Akiyama J
    Expert Opin Drug Saf; 2013 Sep; 12(5):659-72. PubMed ID: 23647006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
    Bruley des Varannes S; Coron E; Galmiche JP
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):905-21. PubMed ID: 21126703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitors--uncommon adverse effects.
    Oh S
    Aust Fam Physician; 2011 Sep; 40(9):705-8. PubMed ID: 21894279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.
    de la Coba Ortiz C; Argüelles Arias F; Martín de Argila de Prados C; Júdez Gutiérrez J; Linares Rodríguez A; Ortega Alonso A; Rodríguez de Santiago E; Rodríguez-Téllez M; Vera Mendoza MI; Aguilera Castro L; Álvarez Sánchez Á; Andrade Bellido RJ; Bao Pérez F; Castro Fernández M; Giganto Tomé F
    Rev Esp Enferm Dig; 2016 Apr; 108(4):207-24. PubMed ID: 27034082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton Pump Inhibitor Use in Older Adults: Long-Term Risks and Steps for Deprescribing.
    Pezeshkian S; Conway SE
    Consult Pharm; 2018 Sep; 33(9):497-503. PubMed ID: 30185290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
    Howell MD; Novack V; Grgurich P; Soulliard D; Novack L; Pencina M; Talmor D
    Arch Intern Med; 2010 May; 170(9):784-90. PubMed ID: 20458086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
    Laine L; Hennekens C
    Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM; McIntyre L; Bernard L; Fendrick AM
    Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms.
    Corsonello A; Lattanzio F; Bustacchini S; Garasto S; Cozza A; Schepisi R; Lenci F; Luciani F; Maggio MG; Ticinesi A; Butto V; Tagliaferri S; Corica F
    Curr Drug Metab; 2018; 19(2):142-154. PubMed ID: 29219052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The risks of long-term proton pump inhibitors use].
    Jiang X; Zhang Q; Zhang Z; Liu Y
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(4):284-8. PubMed ID: 24731496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
    Hermos JA; Young MM; Fonda JR; Gagnon DR; Fiore LD; Lawler EV
    Clin Infect Dis; 2012 Jan; 54(1):33-42. PubMed ID: 22100573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?
    Ben-Eltriki M; Chhabra M; Cassels A; Wright JM
    Curr Drug Saf; 2024; 19(2):244-247. PubMed ID: 37496243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.
    Singh A; Cresci GA; Kirby DF
    Nutr Clin Pract; 2018 Oct; 33(5):614-624. PubMed ID: 30071147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acid suppression therapy: where do we go from here?
    Scarpignato C; Pelosini I; Di Mario F
    Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
    Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
    Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
    Fournier MR; Targownik LE; Leslie WD
    Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect?
    Kushner PR; Peura DA
    Adv Ther; 2011 May; 28(5):367-88. PubMed ID: 21484335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.